Review



ce-ivd marked surrogate virus neutralization test genscript cpass svnt  (GenScript corporation)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GenScript corporation ce-ivd marked surrogate virus neutralization test genscript cpass svnt
    Study flow chart. Anti-Spike(S)-antibody (Ab) assays: Roche S, Abbott S. Infection with SARS-CoV-2 was ruled out by detection of antibodies against the SARS-CoV-2 nucleocapsid (N) using the Roche N ECLIA. W, weeks; <t>sVNT,</t> surrogate virus <t>neutralization</t> test.
    Ce Ivd Marked Surrogate Virus Neutralization Test Genscript Cpass Svnt, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ce-ivd marked surrogate virus neutralization test genscript cpass svnt/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    ce-ivd marked surrogate virus neutralization test genscript cpass svnt - by Bioz Stars, 2026-05
    90/100 stars

    Images

    1) Product Images from "The Comparability of Anti-Spike SARS-CoV-2 Antibody Tests is Time-Dependent: a Prospective Observational Study"

    Article Title: The Comparability of Anti-Spike SARS-CoV-2 Antibody Tests is Time-Dependent: a Prospective Observational Study

    Journal: Microbiology Spectrum

    doi: 10.1128/spectrum.01402-21

    Study flow chart. Anti-Spike(S)-antibody (Ab) assays: Roche S, Abbott S. Infection with SARS-CoV-2 was ruled out by detection of antibodies against the SARS-CoV-2 nucleocapsid (N) using the Roche N ECLIA. W, weeks; sVNT, surrogate virus neutralization test.
    Figure Legend Snippet: Study flow chart. Anti-Spike(S)-antibody (Ab) assays: Roche S, Abbott S. Infection with SARS-CoV-2 was ruled out by detection of antibodies against the SARS-CoV-2 nucleocapsid (N) using the Roche N ECLIA. W, weeks; sVNT, surrogate virus neutralization test.

    Techniques Used: Infection, Virus, Neutralization

    (A) Antibody levels (Roche, Abbott) and percent inhibition in a surrogate virus neutralization test (sVNT) 3 wk (weeks) after the first dose of AZD1222, prebooster (11w after the first dose), and 3 wk postbooster. Dotted lines indicate the test system threshold for positivity (Roche: 0.8 BAU/mL, Abbott 7.1 BAU/mL, sVNT 30%) and, in the case of Roche, the upper level of quantification (2,500 BAU/mL). Green lines represent the group median. ****, P < 0.0001 in Wilcoxon tests. (B) Longitudinal changes of individual Roche, Abbott, and cPass surrogate virus neutralization test (sVNT) results: 3 wk (3 weeks) after the first dose, before the booster dose, and 3 wk after the booster dose. According to the manufacturers, Roche results ≥15 BAU/mL correlate with a positive neutralization test, Abbott results ≥149,1 BAU/mL correspond to a neutralization titer of at least 1:80; 30% inhibition is considered the sVNTs threshold for positivity. Results are, according to the manufacturer, categorized into low (30 to 60%), medium (60 to 90%), and high (>90%) neutralizing capacity (all levels indicated by dotted lines).
    Figure Legend Snippet: (A) Antibody levels (Roche, Abbott) and percent inhibition in a surrogate virus neutralization test (sVNT) 3 wk (weeks) after the first dose of AZD1222, prebooster (11w after the first dose), and 3 wk postbooster. Dotted lines indicate the test system threshold for positivity (Roche: 0.8 BAU/mL, Abbott 7.1 BAU/mL, sVNT 30%) and, in the case of Roche, the upper level of quantification (2,500 BAU/mL). Green lines represent the group median. ****, P < 0.0001 in Wilcoxon tests. (B) Longitudinal changes of individual Roche, Abbott, and cPass surrogate virus neutralization test (sVNT) results: 3 wk (3 weeks) after the first dose, before the booster dose, and 3 wk after the booster dose. According to the manufacturers, Roche results ≥15 BAU/mL correlate with a positive neutralization test, Abbott results ≥149,1 BAU/mL correspond to a neutralization titer of at least 1:80; 30% inhibition is considered the sVNTs threshold for positivity. Results are, according to the manufacturer, categorized into low (30 to 60%), medium (60 to 90%), and high (>90%) neutralizing capacity (all levels indicated by dotted lines).

    Techniques Used: Inhibition, Virus, Neutralization

    Linear regression lines (±95% confidence intervals) for c-pass surrogate virus neutralization test (sVNT) results and logarithmic binding assay results (top, Abbott; bottom, Roche). The dotted vertical line represents the sVNT threshold for positivity (30% inhibition). According to the manufacturers, Roche results ≥15 BAU/mL correlate with a positive neutralization test, Abbott results ≥149,1 BAU/mL correspond to a neutralization titer of at least 1:80 as indicated by horizontal dotted lines. 3 wk, 3 weeks; BAU/mL, binding antibody units per milliliter.
    Figure Legend Snippet: Linear regression lines (±95% confidence intervals) for c-pass surrogate virus neutralization test (sVNT) results and logarithmic binding assay results (top, Abbott; bottom, Roche). The dotted vertical line represents the sVNT threshold for positivity (30% inhibition). According to the manufacturers, Roche results ≥15 BAU/mL correlate with a positive neutralization test, Abbott results ≥149,1 BAU/mL correspond to a neutralization titer of at least 1:80 as indicated by horizontal dotted lines. 3 wk, 3 weeks; BAU/mL, binding antibody units per milliliter.

    Techniques Used: Virus, Neutralization, Binding Assay, Inhibition

    Spearman’s ρ of rank correlations between Nil-corrected interferon γ (IFN-γ) levels after incubation with Quantiferon SARS-CoV-2 antigen mixtures 1 (Ag1-Nil) or 2 (Ag2-Nil) and antibody levels <xref ref-type= a " title="Spearman’s ρ of rank correlations between Nil-corrected interferon γ (IFN-γ) levels after incubation ... " property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Spearman’s ρ of rank correlations between Nil-corrected interferon γ (IFN-γ) levels after incubation with Quantiferon SARS-CoV-2 antigen mixtures 1 (Ag1-Nil) or 2 (Ag2-Nil) and antibody levels a

    Techniques Used: Incubation



    Similar Products

    ce-ivd marked surrogate virus neutralization test genscript cpass svnt  (GenScript corporation)
    90
    GenScript corporation ce-ivd marked surrogate virus neutralization test genscript cpass svnt
    Study flow chart. Anti-Spike(S)-antibody (Ab) assays: Roche S, Abbott S. Infection with SARS-CoV-2 was ruled out by detection of antibodies against the SARS-CoV-2 nucleocapsid (N) using the Roche N ECLIA. W, weeks; <t>sVNT,</t> surrogate virus <t>neutralization</t> test.
    Ce Ivd Marked Surrogate Virus Neutralization Test Genscript Cpass Svnt, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ce-ivd marked surrogate virus neutralization test genscript cpass svnt/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    ce-ivd marked surrogate virus neutralization test genscript cpass svnt - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Study flow chart. Anti-Spike(S)-antibody (Ab) assays: Roche S, Abbott S. Infection with SARS-CoV-2 was ruled out by detection of antibodies against the SARS-CoV-2 nucleocapsid (N) using the Roche N ECLIA. W, weeks; sVNT, surrogate virus neutralization test.

    Journal: Microbiology Spectrum

    Article Title: The Comparability of Anti-Spike SARS-CoV-2 Antibody Tests is Time-Dependent: a Prospective Observational Study

    doi: 10.1128/spectrum.01402-21

    Figure Lengend Snippet: Study flow chart. Anti-Spike(S)-antibody (Ab) assays: Roche S, Abbott S. Infection with SARS-CoV-2 was ruled out by detection of antibodies against the SARS-CoV-2 nucleocapsid (N) using the Roche N ECLIA. W, weeks; sVNT, surrogate virus neutralization test.

    Article Snippet: Binding reactivities (Roche, Abbott) were compared to a well-described CE-IVD marked surrogate virus neutralization test (GenScript cPass sVNT) ( , ).

    Techniques: Infection, Virus, Neutralization

    (A) Antibody levels (Roche, Abbott) and percent inhibition in a surrogate virus neutralization test (sVNT) 3 wk (weeks) after the first dose of AZD1222, prebooster (11w after the first dose), and 3 wk postbooster. Dotted lines indicate the test system threshold for positivity (Roche: 0.8 BAU/mL, Abbott 7.1 BAU/mL, sVNT 30%) and, in the case of Roche, the upper level of quantification (2,500 BAU/mL). Green lines represent the group median. ****, P < 0.0001 in Wilcoxon tests. (B) Longitudinal changes of individual Roche, Abbott, and cPass surrogate virus neutralization test (sVNT) results: 3 wk (3 weeks) after the first dose, before the booster dose, and 3 wk after the booster dose. According to the manufacturers, Roche results ≥15 BAU/mL correlate with a positive neutralization test, Abbott results ≥149,1 BAU/mL correspond to a neutralization titer of at least 1:80; 30% inhibition is considered the sVNTs threshold for positivity. Results are, according to the manufacturer, categorized into low (30 to 60%), medium (60 to 90%), and high (>90%) neutralizing capacity (all levels indicated by dotted lines).

    Journal: Microbiology Spectrum

    Article Title: The Comparability of Anti-Spike SARS-CoV-2 Antibody Tests is Time-Dependent: a Prospective Observational Study

    doi: 10.1128/spectrum.01402-21

    Figure Lengend Snippet: (A) Antibody levels (Roche, Abbott) and percent inhibition in a surrogate virus neutralization test (sVNT) 3 wk (weeks) after the first dose of AZD1222, prebooster (11w after the first dose), and 3 wk postbooster. Dotted lines indicate the test system threshold for positivity (Roche: 0.8 BAU/mL, Abbott 7.1 BAU/mL, sVNT 30%) and, in the case of Roche, the upper level of quantification (2,500 BAU/mL). Green lines represent the group median. ****, P < 0.0001 in Wilcoxon tests. (B) Longitudinal changes of individual Roche, Abbott, and cPass surrogate virus neutralization test (sVNT) results: 3 wk (3 weeks) after the first dose, before the booster dose, and 3 wk after the booster dose. According to the manufacturers, Roche results ≥15 BAU/mL correlate with a positive neutralization test, Abbott results ≥149,1 BAU/mL correspond to a neutralization titer of at least 1:80; 30% inhibition is considered the sVNTs threshold for positivity. Results are, according to the manufacturer, categorized into low (30 to 60%), medium (60 to 90%), and high (>90%) neutralizing capacity (all levels indicated by dotted lines).

    Article Snippet: Binding reactivities (Roche, Abbott) were compared to a well-described CE-IVD marked surrogate virus neutralization test (GenScript cPass sVNT) ( , ).

    Techniques: Inhibition, Virus, Neutralization

    Linear regression lines (±95% confidence intervals) for c-pass surrogate virus neutralization test (sVNT) results and logarithmic binding assay results (top, Abbott; bottom, Roche). The dotted vertical line represents the sVNT threshold for positivity (30% inhibition). According to the manufacturers, Roche results ≥15 BAU/mL correlate with a positive neutralization test, Abbott results ≥149,1 BAU/mL correspond to a neutralization titer of at least 1:80 as indicated by horizontal dotted lines. 3 wk, 3 weeks; BAU/mL, binding antibody units per milliliter.

    Journal: Microbiology Spectrum

    Article Title: The Comparability of Anti-Spike SARS-CoV-2 Antibody Tests is Time-Dependent: a Prospective Observational Study

    doi: 10.1128/spectrum.01402-21

    Figure Lengend Snippet: Linear regression lines (±95% confidence intervals) for c-pass surrogate virus neutralization test (sVNT) results and logarithmic binding assay results (top, Abbott; bottom, Roche). The dotted vertical line represents the sVNT threshold for positivity (30% inhibition). According to the manufacturers, Roche results ≥15 BAU/mL correlate with a positive neutralization test, Abbott results ≥149,1 BAU/mL correspond to a neutralization titer of at least 1:80 as indicated by horizontal dotted lines. 3 wk, 3 weeks; BAU/mL, binding antibody units per milliliter.

    Article Snippet: Binding reactivities (Roche, Abbott) were compared to a well-described CE-IVD marked surrogate virus neutralization test (GenScript cPass sVNT) ( , ).

    Techniques: Virus, Neutralization, Binding Assay, Inhibition

    Spearman’s ρ of rank correlations between Nil-corrected interferon γ (IFN-γ) levels after incubation with Quantiferon SARS-CoV-2 antigen mixtures 1 (Ag1-Nil) or 2 (Ag2-Nil) and antibody levels <xref ref-type= a " width="100%" height="100%">

    Journal: Microbiology Spectrum

    Article Title: The Comparability of Anti-Spike SARS-CoV-2 Antibody Tests is Time-Dependent: a Prospective Observational Study

    doi: 10.1128/spectrum.01402-21

    Figure Lengend Snippet: Spearman’s ρ of rank correlations between Nil-corrected interferon γ (IFN-γ) levels after incubation with Quantiferon SARS-CoV-2 antigen mixtures 1 (Ag1-Nil) or 2 (Ag2-Nil) and antibody levels a

    Article Snippet: Binding reactivities (Roche, Abbott) were compared to a well-described CE-IVD marked surrogate virus neutralization test (GenScript cPass sVNT) ( , ).

    Techniques: Incubation